Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cue Biopharma (CUE) Net Margin (2018 - 2025)

Cue Biopharma's Net Margin history spans 8 years, with the latest figure at 340.34% for Q3 2025.

  • For Q3 2025, Net Margin fell 8636.0% year-over-year to 340.34%; the TTM value through Sep 2025 reached 524.36%, down 6835.0%, while the annual FY2024 figure was 429.4%, 47202.0% up from the prior year.
  • Net Margin for Q3 2025 was 340.34% at Cue Biopharma, down from 285.74% in the prior quarter.
  • Across five years, Net Margin topped out at 95.58% in Q4 2021 and bottomed at 50796.15% in Q2 2022.
  • The 5-year median for Net Margin is 705.07% (2024), against an average of 4946.33%.
  • The largest annual shift saw Net Margin tumbled -5042087bps in 2022 before it skyrocketed 4985957bps in 2023.
  • A 5-year view of Net Margin shows it stood at 95.58% in 2021, then tumbled by -9763bps to 9426.49% in 2022, then surged by 92bps to 710.27% in 2023, then rose by 17bps to 592.83% in 2024, then skyrocketed by 43bps to 340.34% in 2025.
  • Per Business Quant, the three most recent readings for CUE's Net Margin are 340.34% (Q3 2025), 285.74% (Q2 2025), and 2881.0% (Q1 2025).